Tovinontrine
Small moleculeexperimental
Clinical trial activity
8 trials · 5 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
7
Phase 3
0
Phase 4
0
Earliest trial started Nov 1, 2016 (NCT02998450)
Timeline
Indications
Mechanism of action
- Phosphodiesterase 9AINHIBITOR
PDE9A inhibitor
Chemistry & pharmacology
Loading structure…
SMILES
C[C@@H]1CN(Cc2ncccn2)C[C@H]1c1cn2c(C3CCOCC3)ncc2c(=O)[nH]1- Mol. weight
- 394.48 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL4297290 ↗
Also known as
- imr-687
- imr-687
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06215911 | Phase 2 | Feb 13, 2024 | Cardurion Pharmaceuticals, Inc. |
| NCT06215586 | Phase 2 | Feb 13, 2024 | Cardurion Pharmaceuticals, Inc. |
| NCT05312021 | Phase 2 | Apr 30, 2022 | Imara, Inc. |
| NCT04474314 | Phase 2 | Aug 13, 2020 | Imara, Inc. |
| NCT04411082 | Phase 2 | Jun 30, 2020 | Imara, Inc., The Oncology Institute Long Beach |
| NCT04053803 | Phase 2 | May 22, 2019 | Guy's and St Thomas Hospital, Imara, Inc. |
| NCT03401112 | Phase 2 | Jan 26, 2018 | Guy's and St Thomas Hospital, Imara, Inc. |
| NCT02998450 | Phase 1 | Nov 1, 2016 | Imara, Inc., IQVIA |
Showing 8 of 8 trials
Page 1 / 1
Organizations
Research & Development (5)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Imara, Inc. | For profit | 6 | 6 | 2 | 2016 |
| Cardurion Pharmaceuticals, Inc. | For profit | 2 | 2 | 1 | 2024 |
| Guy's and St Thomas Hospital | Academic/Hospital | 2 | 0 | 1 | 2018 |
| IQVIA | For profit | 1 | 0 | 1 | 2016 |
| The Oncology Institute Long Beach | Academic/Hospital | 1 | 0 | 1 | 2020 |
5 organizations
Page 1 / 1